MADD is a disorder of fatty acid and protein metabolism caused by a defect of the electron transfer flavoprotein or the electron transfer flavoprotein ubiquinone oxidoreductase. Patients with MADD have been classified in three groups: neonatal onset with congenital anomalies, neonatal onset without anomalies, and mild or later onset (1) . Patients in the first group are often premature and present soon after birth with hypotonia and hepatomegaly. Some dysmorphic features may be present: high forehead, hypoplastic midface, wide-open anterior fontanel, defects of the anterior abdominal wall, abnormal genitalia, and renal cysts. Most patients die within the first week of life (1, 2) . Patients in the second group do not have congenital anomalies, but their clinical presentation is otherwise similar to the first one. Children in this group usually develop severe cardiomyopathy and die during the first few weeks of life (1) . The course and presentation of the late-onset patients is extremely variable, ranging from episodes of vomiting with hypoglycemia and hepatomegaly to progressive lipid storage myopathy in adulthood (3) (4) (5) .
The diagnosis of MADD is suspected on the basis of the clinical and biochemical presentation. Common laboratory abnormalities are hypoglycemia with hypoketosis and mild met-abolic acidosis. Analysis of the organic acids or acylglycines in urine shows a characteristic profile. However, these abnormalities may be present only when patients are under stress (6) . More recently, the analysis of AC by MS-MS has been used for the biochemical diagnosis of MADD (7, 8) . This method is also being used for neonatal diagnosis through newborn screening programs. However, its sensitivity for the neonatal detection of MADD has been questioned, and, to our knowledge, only one patient has been reported to be prospectively diagnosed in a newborn screening program (9) .
The recommended long-term treatment of MADD includes riboflavin, carnitine, or glycine, and a low-fat, low-protein, high-carbohydrate diet, avoiding long periods of fasting (1, 2, 10 -13). However, assessment of the patients' metabolic status when they are not in crisis is difficult because there is no useful biochemical marker to determine the response to different dietary treatments or periods of fasting. Additionally, there is limited information about the long-term outcome of these patients.
The aims of this study are to report the diagnosis of a patient with MADD through a newborn screening program using MS-MS, to assess her biochemical response to different feeds during short fasting periods, and to evaluate the usefulness of AC and FFA to monitor the response to these dietary changes.
METHODS

Patient
Family history. There was a history of consanguinity and three dead siblings: the first one (boy) died, unexpectedly, at age 7 d; the second one (girl) died at 1 y of age with a sepsis-like episode. The third one (boy) presented at the age of 9 mo with a Reye-like syndrome. Diagnosis of a severe MADD was established at the time on the basis of the clinical presentation and a typical organic acid profile. Treatment with riboflavin and carnitine was started, but the patient died a few days later.
Initial presentation. The patient was the female product of a full-term pregnancy. She was born via cesarean section with a birth weight of 3400 g. Physical examination was normal except for a wide-open anterior fontanel and a high forehead. A Guthrie card sample was sent at age 6 d to our laboratory for newborn screening, while patient was asymptomatic. Diagnosis was established on the following day, and treatment with carnitine (Albicar, Casasco, Buenos Aires, Argentina, 100 mg·kg Ϫ1 ·d Ϫ1 , divided in three doses) was immediately started. Riboflavin (200 mg/d, divided in two doses) was added 4 d later. Pretreatment glucose, liver enzymes, and riboflavin levels, as well as renal ultrasound, were normal.
Diet
From birth until the age of 3 mo, the patient was breast-fed every 3-4 h. From 3 mo on, the patient has been on treatment with a low-fat (15%), low-protein (7%), high-carbohydrate (78%) diet, providing 90 -120 calories·kg Ϫ1 ·d Ϫ1 (adjusted according to age and weight gain). From 3 to 6 mo of age, the diet was given as F feedings every 4 h. After 6 mo of age, semisolids were started, and at 9 mo uncooked CS was gradually incorporated. After the results of test number 4 were available (see below), pancreatic enzymes (Prolipase, Janssen-Cilag, Buenos Aires, Argentina), at a dose of 40,000 IU of A, were given before the F.
Protocol
To assess the patient's response to different feeds and fasting periods, five tests were performed during the first year of life. The initial one was done while the patient was receiving BM. The following four tests were performed by giving the patient a bottle, prepared with F (Similac, Abbot, Buenos Aires, Argentina), 1.2 g/kg, a low-fat milk (Molico, Nestlé, Buenos Aires, Argentina), 0.7 g/kg, and different types of carbohydrates: GP (Polimerosa, Kasdorf, Buenos Aires, Argentina), 3 g/kg, or GP ϩCS, 1.5 g/kg each. This F feed provided 20 calories/kg (approximately one sixth of the total caloric intake) with the recommended caloric distribution for MADD: carbohydrates, 78%; protein, 7%; and fat, 15%. The tests were performed as outlined in Table 1 . The protocol was approved by the ethics committee of the Fundación para el Estudio de las Enfermedades Neurometabólicas. An informed consent was obtained from the mother before each test. All the tests were performed while the patient was clinically stable, without any sign of intercurrent illness. Liver enzymes and creatine kinase (obtained in the basal sample of each test) were normal. A heparin lock was maintained throughout each test, and blood was obtained for AC, NEFA, insulin, glucose, 3-hydroxybutyrate, amino acids, and total and free carnitine.
Measurements
All the studies were performed at the Fundación para el Estudio de las Enfermedades Neurometabólicas. For AC analysis, blood samples were spotted in a filter paper (Schleicher & Schuell 903, Keene, NH, U.S.A.) and allowed to dry at room temperature. Sample preparation and analysis were performed as described (14, 15) in a Quattro II, triple quadrupole mass spectrometer (Micromass, U.K.) with electrospray. Acquisition was performed scanning for ions parents of m/z 85 (butyl esters). Free, acetyl-(C2), propionyl-(C3), butyryl-(C4), isovaleryl-(C5), octanoyl-(C8), decanoyl-(C10), dodecanoyl-(C12), tetradecanoyl-(C14), hexadecanoyl-(C16), and octadecanoyl-(C18) carnitines were quantitated with their corresponding isotopes. Hexanoylcarnitine (C6) was quantitated using the C8 isotope. Labeled internal standards were obtained from Dr. Herman J. Ten Brink (Academic Hospital V.U., Amsterdam, The Netherlands). Normal values for the newborn period were obtained from 841 normal neonates screened in C]palmitic. Samples for these assays were obtained while the patient was already receiving riboflavin. When enough sample was available, levels of the individual FFA of carbon length C6, C8, C10, C12, C14, C16, and C18 were measured in plasma by gas chromatography-mass spectrometry, using the method of Costa et al. (18) . NEFA, 3-hydroxybutyrate, amino acids, and carnitine were measured as described (19 -22) . Pearson's correlation was used for statistical analysis.
RESULTS
The newborn screening profile showed low levels of C2 and elevations of short-, medium-, and long-chain AC, except for C3 and C16 ( Table 2 ). The unsaturated species C12:1, C14:1, C16:1, and C18:1 were also elevated. No significant changes were observed after treatment with carnitine, except for an increase in C2 levels and a decrease in the long-chain AC, probably age related. Results of AC measured 7 d after treatment with riboflavin showed that, on average, AC values were slightly lower than those obtained before treatment, but remained elevated compared with normal values ( Table 2) .
The oxidation of tritiated fatty acids in lymphocytes was apparently more sensitive than the 14 C substrate oxidations (15-20% versus 34 -41%, respectively; Table 3 ).
To compare the AC, FFA, NEFA, and insulin responses during the tests, we calculated the sum of the AC C6, C8, C10, C12, C14, C16, and C18 and that of the corresponding FFA for each fasting time. Results are shown in Table 4 and Figure 1 . The tests, performed at age 3 mo, revealed that when the patient received BM (test number 1), the AC, FFA, and NEFA were elevated, whereas insulin levels tended to be low. When the patient was given FϩGP (test number 2), AC, FFA, and NEFA markedly decreased. This response was associated with an increment in the insulin levels. Test number 3, performed at 6 mo with a similar feed (FϩGP), showed slight elevations of FFA and NEFA at 2 and 4 h, with a clear increase of AC, FFA, and NEFA in the 6-h sample (Ն100% versus the 4-h values). Insulin levels tended to decrease throughout the test and were lower than those of test number 2. In an attempt to avoid the increase of AC, FFA, and NEFA at 6 h, uncooked complex carbohydrates (CS) were gradually added to the diet, maintaining the total amount of carbohydrates unchanged. However, when the feed with FϩGPϩCS was tested (test number 4), the AC and NEFA showed mild elevations at Insulin values showed negative correlations with AC (r ϭ Ϫ0.43, NS), FFA (r ϭ Ϫ0.60, p Ͻ 0.05), and NEFA (r ϭ Ϫ0.59, p Ͻ 0.05).
The results of individual AC values measured during the tests showed that C3, C16, and C18 remained within normal limits in all tests, whereas C4 and C5 remained abnormal despite the dietary changes. Levels of C2 remained at the low normal limits in all tests, regardless of fasting. Values of individual FFA showed a pattern similar to that of the corresponding AC (data not shown). Accordingly, significant correlations were found between the individual AC and the corresponding FFA, with p Ͻ 0.001 for C6 (r ϭ 0.988), C8 (r ϭ 0.882), C10 (r ϭ 0.924), and C14 (r ϭ 0.948) and p Ͻ 0.02 for C12 (r ϭ 0.672) and C16 (r ϭ 0.681; n ϭ11 for each carbon length).
The patient is currently 3.9 years old. Her weight is slightly above the 97th percentile, length is at the 75th percentile, and head circumference is at the 95th percentile. She continues with a low-fat, low-protein, high-carbohydrate diet. CS is given four times a day, mixed with F, juice, or water. Amylase was discontinued. She has had a few intercurrent illnesses with no decompensations, and her neurologic examination and development are normal.
DISCUSSION
MADD is a disorder of fatty acid and protein metabolism for which diet is considered part of the treatment (1, 2) . However, there is little information about the optimal composition of the diet, the type of carbohydrate to be given, the fasting periods that are safe for the patients at different ages, and the expected long-term clinical and biochemical outcome. Follow-up of the patients is complicated by the fact that some of the biochemical markers of the disease, like glucose levels or organic acids, will be abnormal only when patients are under stress. Therefore, there is a need for a biochemical marker that will be sensitive enough to reflect variations in diet or fasting, when the patients are not in crisis.
We report the diagnosis of a patient with MADD through a newborn screening program using MS-MS, and the biochemical response of this patient to different feeds to evaluate the usefulness of AC and FFA to monitor the response to these dietary changes.
It is known that patients with MADD can present with a wide range of severity (1, 2) . The family history and the physical examination of our patient suggest an intermediateto-severe form of the disease. It has been suggested that neonatal detection of MADD through newborn screening programs using MS-MS may not be reliable for all cases, and, to our knowledge, only one patient has been prospectively detected in such a program (9) . However, in the present case, the levels of short-, medium-, and long-chain AC obtained on the sixth day of life, while the patient was asymptomatic, were clearly abnormal. The AC profile was similar to that reported for older children with MADD (7, 8) . However, comparison of the actual AC values is difficult because AC levels in children with fatty acid oxidation defects vary with age, metabolic status, and fasting period, and these data were not provided in previous reports. Additionally, internal standards used in those studies for quantitation were different (7, 8) .
Results of the oxidation of palmitic and myristic acids were similar to those reported by Brivet et al. (16) in a patient with MADD who presented clinically at 2 y of age. The oxidation of 14 C-labeled fatty acids was also consistent with MADD. As riboflavin can modify the results of the oxidation tests performed in fibroblasts, (WR Rhead, personal communication, 1999), it is possible that the results of our studies in lymphocytes could have also been modified by the vitamin treatment.
Results of tests 1 and 2 showed that breast-feedings were associated with markedly increased levels of AC, FFA, and NEFA and that these values tended to normalize when a low-fat, low-protein, high-carbohydrate diet was given. This biochemical response shows that the recommended dietary treatment for MADD allows a good metabolic control and that breast-feedings should probably be avoided. When the patient was 6 mo old, test number 3 was performed to determine her biochemical response to a fasting period Ͼ4 h. Even though the patient was under good metabolic control, receiving the recommended diet and maintaining normal blood sugar levels during the test, there was a clear increase in AC, FFA, and NEFA levels after 6 h of fasting. These results are in agreement with those observed for MCAD deficiency (23), very longchain acyl-CoA dehydrogenase deficiency (24) , and long-chain hydroxy-acyl-CoA dehydrogenase deficiency (25) and highlight the importance of fasting control in children with fatty acid oxidation defects.
It has been suggested that CS, as used for glycogen storage diseases, could be used a source of slow-release carbohydrates to avoid the effects of fasting in children with fatty acid oxidation defects (13) . We have documented that CS decreases the levels of octanoylcarnitine in children with MCAD deficiency (23) . However, CS may not be useful in children Ͻ2 y of age because they may not have enough endogenous A activity (26) . It has been suggested that giving CS in progressively increasing amounts over time may be helpful to overcome that problem (27) . However, the results obtained in test number 4 suggested that in spite of giving CS progressively for a period of 4 mo, the patient's endogenous A activity was not enough to break down the CS given. When exogenous A was 
64
given before the formula (test number 5), levels of AC, FFA, and NEFA tended to normalize even at 6 h, suggesting that the exogenous enzyme allowed the proper carbohydrate breakdown These results are in agreement with the report of Schiffrin et al. (28) in a 9-mo-old patient with glycogen storage disease type I. This therapeutic approach may be an alternative to the use of continuous overnight feedings (through nasogastric tube or gastrostomy), which have been suggested for young children with severe fatty acid oxidation defects (13).
Dietary treatment of MADD is aimed at decreasing the use of fatty acids and protein as a fuel, which can result in the accumulation of toxic compounds. For that reason it is essential to avoid long periods of fasting, which would mobilize FFA from adipose tissue stores and activate the lipolytic pathway. Additionally, the high-carbohydrate diet is supposed to increase endogenous insulin secretion, which will suppress lipolysis and stimulate lipogenesis. We demonstrate that levels of insulin vary inversely with levels of AC, FFA, and NEFA. This negative correlation suggests that changes of those metabolites are secondary to changes in the insulin levels, which are induced by the different carbohydrate composition of the diet.
The use of AC for the diagnosis of fatty acid oxidation defects is now widely accepted; however, there is little information about the use of these compounds for the follow-up of the patients. For that purpose it is important to be sure that variations in AC levels reflect changes in the levels of fatty acids, which are likely to be the toxic compounds (29) . The significant correlations found in our study between the different carbon length AC and the corresponding FFA are in agreement with our previous report in MCAD deficiency (23) , and validate the usefulness of measuring the former as a marker of the metabolic status of the patient. Owing to the simple blood collection, monitoring of AC would be the method of choice for those centers with access to MS-MS technology coupled with a fast turn-around time. However, it is important to consider the time of the sample in relation to fasting, to be sure that normal levels of free carnitine are maintained and that valproic acid-or pivalic acid-containing drugs are not given (30) .
As previously reported for MCAD deficiency (31) , this patient's outcome and family history suggest that early diagnosis and treatment can change the natural history of MADD. Figure 1 . Results of the five tests. Test number 1 was performed while the patient was receiving BM. The following tests (numbers 2-5) were performed by giving the patient a bottle of F with the recommended nutrient composition for MADD: carbohydrates, 78%; protein, 7%; and fat, 15%. The formula was prepared mixing an infant formula, a low-fat milk, and different types of carbohydrates: GP for tests 2 and 3, and a mixture of GPϩCS) for tests 4 and 5. Amylase was given in test number 5 immediately before the formula. Samples were obtained every 2 h in each test. More details are outlined in Table 1 and in the text (see Methods).
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MULTIPLE ACYL-CoA-DEHYDROGENASE DEFICIENCY (MADD)
